San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
Two professors of psychiatry at University of California, San Diego School of Medicine have been honored by the New York City-based Brain & Behavior Research Foundation for their work studying the genetics, dysfunction and treatment of schizophrenia, a chronic and severe brain disorder affecting roughly 1 percent of the general population or approximately 3 million people.
Decision Resources Group Announces Its Managed Care Account Management Training Seminar to be Held Next Month in San Francisco
BURLINGTON, Mass., Oct. 7, 2014 /PRNewswire/ – Account Management Training (AMT) presented by Decision Resources Group is a three-day conference providing comprehensive, hands-on training that will give account managers knowledge, techniques, and confidence to successfully work with their managed care accounts. AMT is considered a “gold-standard” within the pharmaceutical and biotech industry training over 1,000 account managers.
Conference presenters include:
Neil Minkoff, MD – Founder and CEO, FountainHead HealthCare
James T. Kenney, Jr., RPh, MBA, Pharmacy Operations Manager, Harvard Pilgrim Health Care, Inc.
Patrick W. Finnerty – PWF Consulting
Charles Bell – Director, New Business Development, Express Scripts
Kirby J. Eng, RPh – Executive Director, Clinical Oncology Management Services, Onco 360
William Fleming, PharmD – Segment Vice President, Humana Inc., President, Humana Pharmacy Solutions
Rebecca Waller – Principal Training Consultant, Decision Resources GroupAMT will take place at The Hyatt Regency in San Francisco on November 18-20, 2014. The cost is $3,795 per person with discounts available to groups of three or more. For more information and to register, click here.
Media interested in attending the conference should contact Briana Pontremoli at firstname.lastname@example.org or 781-993-2654 for additional information.
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group Briana Pontremoli 781-993-2654 email@example.com
Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO
SOURCE Decision Resources Group
Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach and small intestine. One key finding: Patients of Asian descent, who have not previously been identified as an at-risk population, are 1.5 times more likely than other patient groups to be diagnosed with this type of tumor.
Digital health is popular among investors, there’s no doubt. But is it good for us? Products such as fitness wristbands and online wellness coaching are generating buzz, and as a techno-skeptic…
[[Click headline to continue reading.]]
Researchers at the University of California, San Diego School of Medicine have identified a microRNA molecule as a surprisingly crucial player in managing cell survival and growth. The findings underscore the emerging recognition that non-coding RNAs help regulate basic cellular processes and may be key to developing new drugs and therapies.
SAN DIEGO, Oct. 7, 2014 /PRNewswire/ — Formex LLC (“Formex”), a leader in pharmaceutical formulation development and manufacturing, announced today an expansion in both scientific personnel and equipment.
Dr. Ke Shi and Dr. Wade Pathak recently joined Formex with extensive expertise in areas critical to pharmaceutical development. Dr. Pathak, a coauthor of 20 patents and 50 publications, will be employing his diverse experience in the pharmaceutical industry in formulation development and analytical chemistry. Dr. Ke Shi is an expert in spray dry dispersion technology with specific applications in drug taste masking, pulmonary delivery of proteins/peptides, and controlled release of flavors and fragrances. The two PhDs are looking forward to contributing to Formex’s contract development services.
“The addition of Dr. Pathak and Dr. Shi to the scientific staff shows Formex’s commitment to operate at the cutting edge of the industry,” said Yvonne Verburgt, Senior Director of Business Development of Formex. “There are many companies that do contract development and manufacturing, what differentiates Formex is our scientific expertise and approach. Having expert scientists as part of our team allows us to take on difficult projects with the confidence that we can deliver the solutions our Clients need.”
In addition to new staff, Formex LLC has also added to its inventory of manufacturing equipment with the addition of a Capsugel Xcelodose® and a Niro Mobile Minor™. “The acquisition of additional equipment allows Formex to increase its service offering and scale of manufacturing,” said Steve Massah, President and CEO.
About Formex LLC
Formex LLC (“Formex”), The Formulation Experts, is a leading contract development and manufacturing organization focusing on oral and topical dosage forms. Formex specializes in bioavailability enhancement and controlled release technologies, such as hot melt extrusion, spray drying, fluid bed processing, and liquid/semi-solid filled hard capsules.
To learn more about Formex, register for facility tours during AAPS, which is being held November 3-5 in San Diego, CA or contact Formex at www.formexllc.com
Logo – http://photos.prnewswire.com/prnh/20130718/MM49948LOGO
SOURCE Formex LLC
FOSTER CITY, Calif., Oct. 7, 2014 /PRNewswire/ — GeneSolve announced today that it will begin licensing its proprietary health optimization system to a network of highly qualified doctors nationwide. With this change, patients can now have some of the costs of this customized preventative care reimbursed through many insurance programs.
Having proved the efficacy of GeneSolve’s system by successfully attracting and treating hundreds of patients through GeneSolve staff doctors over the past year, the company will be now be able to meet increased demand by installing their proprietary A.I. Software directly in doctor’s offices across the country.
The software–called Arthur in homage to Sir Arthur Conan Doyle–will allow GeneSolve affiliate doctors to provide GeneSolve’s unmatched level of precision health care to their patients in a personalized way.
This individualized approach helps patients as well doctors. Patients with balanced body chemistry benefit from improved energy, mental acuity, and weight loss. Doctors improve the care that they can offer their patients and strengthen the operational efficiency and profitability of their practice.
This new direction for GeneSolve carries two major benefits to patients: First, GeneSolve’s cash-pay model can now be partially covered by many insurance programs, making it more affordable. Second, an expanded network of doctors will make the service more accessible.
For doctors, the new direction eases their entry into a hybrid concierge model and expands their ability to utilize a more complete analytical picture of a patient’s health. They can now incorporate DNA information, an extensive list of biomarkers, and an algorithm-driven patient history.
Doctors who previously were forced by time constraints to maintain a narrow focus on their patients’ problems can now process the larger picture of a patient’s health, including disease prevention and health optimization.
Doctors are now lining up to add GeneSolve to their practices. Dr. Marland Chancellor of Palo Alto, California, was one of the first to incorporate the GeneSolve system into his existing primary care practice. “It’s a phenomenal toolkit,” he said. “No doctor on his or her own would be able to process this much data about each patient so quickly and precisely. GeneSolve makes it possible and improves patient outcomes more quickly and holistically than I have been able to achieve without the technology. I can already see it in my patients, and so can their families, friends, and co-workers. I’ve been looking for a system like this for a long time.”
Noted Chicago-based Cardiologist Dr. Joel Okner agreed, signing on to be GeneSolve’s first doctor in the Mid-West. “GeneSolve provides a way of actually making people better instead of just treating disease,” Dr. Okner said. “GeneSolve allows me as a doctor to maximize the health potential of my patients. It’s really the next step in the evolution of how we treat patients. GeneSolve really got this right.”
GeneSolve’s Medical Director and Co-Founder, Dr. Richard Lee, has a 30-year medical history in health optimization. This includes his long history with artificial intelligence systems in health care. “I’ve been developing and using artificial intelligence software systems, or ‘Expert Systems’, since the early 1980′s when I did an observational study of the Oncocin System at Stanford. It was the first A.I. system of it’s kind, which was designed to help doctors determine the best treatment options for lymphoma,” said Dr. Lee. “Until now, expert systems in medicine were focused on treating exotic and expensive diseases. GeneSolve’s health optimization system is the first to be developed specifically for individualized disease prevention as well as the promotion and development of optimized health. What’s more, we’re now able to include actionable genomic data into the diagnosis and treatment. That wasn’t possible even just a few years ago. Now we’re able to not only incorporate this data but also keep the system updated with the newest research.”
CEO and Founder Jon Orban created GeneSolve as a direct result of a near-death experience when he was hit by a car while riding his bike. Through his recovery, he discovered a large gap between what science already knew and what doctors were equipped to provide. “GeneSolve brings doctors a phenomenally powerful set of tools to help them make better decisions,” said Orban. “GeneSolve can never replace the doctor, but it can make them more accurate across a much wider spectrum of treatment options and they can do it in a way that’s not one-size-fits-all. Now that we can license the entire system to doctors, I’m more confident than ever that we can make a massive difference in the way health care is approached and delivered in this country.”
About GeneSolveFounded in the San Francisco Bay Area in 2012, GeneSolve is the world’s first Body Chemistry Company, providing personalized care via quantifiable biometrics and actionable DNA markers to deliver optimal health. GeneSolve’s evidence-based scientific treatments improve a patient’s quality of life by increases in energy and mental acuity, as well as sustained weight loss. GeneSolve’s A.I. system was created through a collaboration of Stanford physicians, utilizing their decades of experience and the latest in clinical research. It is backed by a growing list of doctors who provide GeneSolve through their practices, and their satisfied GeneSolve patients. The system analyzes extensive DNA, biomarker, and history data for each patient, and then accurately calculates the precise mix of therapies and specific doses needed by each patient, which are custom-compounded and delivered to the patient. To learn more about GeneSolve or to find a GeneSolve doctor in your area, visit www.gene-solve.com
LA JOLLA, Calif., Oct. 7, 2014 /PRNewswire/ — Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech. Other investors in the financing include Brace Pharmaceuticals, Partner Fund Management, L.P. and existing investor Alethea Capital Management. Ben Auspitz from Fidelity Biosciences and Eran Nadav, Ph.D. from TPG Biotech will join Avidity’s board as observers. Proceeds from the financing will be used to advance new cancer therapies that utilize the company’s proprietary antibody-siRNA complex (ARC(TM)) platform.
SAN DIEGO, Oct. 7, 2014 /PRNewswire/ — DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DNX-2401, a conditionally-replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer, the treatment of which remains a significant unmet medical need. Under the designation, companies are provided with development and commercial incentives for designated compounds. The company’s DNX-2401 program has already been granted fast track status.
Reality bites: Amgen’s (NASDAQ: AMGN) decision to leave Washington state is a serious blow to our local bioscience ecosystem. Those who think that all of those people who got laid off (or choose not…
[[Click headline to continue reading.]]